FDA Approves Duvystat, New Oral Treatment for Duchenne Muscular Dystrophy (DMD)
PLOS: DNA Science
MARCH 28, 2024
FDA classifies it as a “nonsteroidal treatment” – not a gene therapy, but it affects gene expression. Results from the study that led to the FDA approval appeared in The Lancet Neurology in April 2024 with commentary. A gene-based treatment would have to alter many cells to exert a noticeable effect.
Let's personalize your content